A61K 47/6415
Toxins or lectins
Official title: {Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins}
A61K47/6415 (Toxins or lectins) appears on 506 US grants and 839 published applications in this corpus.
Search patents in A61K- Granted patents
- 506
- Published applications
- 839
- Assignees
- 357
- Inventors
- 1,379
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1982 | 1 | 0 |
| 1983 | 0 | 0 |
| 1984 | 1 | 0 |
| 1985 | 0 | 0 |
| 1986 | 1 | 0 |
| 1987 | 0 | 0 |
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 5 | 0 |
| 1996 | 1 | 0 |
| 1997 | 3 | 0 |
| 1998 | 5 | 0 |
| 1999 | 9 | 0 |
| 2000 | 8 | 0 |
| 2001 | 4 | 2 |
| 2002 | 10 | 11 |
| 2003 | 5 | 13 |
| 2004 | 4 | 13 |
| 2005 | 4 | 12 |
| 2006 | 4 | 18 |
| 2007 | 8 | 13 |
| 2008 | 9 | 23 |
| 2009 | 2 | 28 |
| 2010 | 11 | 33 |
| 2011 | 16 | 29 |
| 2012 | 11 | 22 |
| 2013 | 16 | 31 |
| 2014 | 18 | 30 |
| 2015 | 29 | 53 |
| 2016 | 30 | 35 |
| 2017 | 23 | 27 |
| 2018 | 31 | 49 |
| 2019 | 22 | 56 |
| 2020 | 35 | 60 |
| 2021 | 33 | 43 |
| 2022 | 41 | 66 |
| 2023 | 33 | 57 |
| 2024 | 24 | 48 |
| 2025 | 36 | 39 |
| 2026 | 10 | 28 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Carbocyclic derivatives and conjugated derivatives thereof, and their use in vaccines11 Aug 2026US 12,702,705 B2Glaxosmithkline Biologicals SA
- Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof26 May 2026US 12,636,374 B2Pfizer Inc.
- Antibodies targeting Fc receptor-like 5 and methods of use26 May 2026US 12,636,375 B2Eureka Therapeutics, Inc.
- Vaccine19 May 2026US 12,629,409 B2Glaxosmithkline Biologicals SA
- Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof5 May 2026US 12,616,744 B2Pfizer Inc.
- Peptide saporin conjugate for the treatment of cancer3 Sep 2026US 2026/0256928 A1SRI International
- Immunogenic Composition20 Aug 2026US 2026/0240990 A1Glaxosmithkline Biologicals SA
- Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof6 Aug 2026US 2026/0224683 A1Pfizer Inc.
- Immunogenic compositions for use in pneumococcal vaccines30 Jul 2026US 2026/0216309 A1Pfizer Inc.
- Compositions and methods for treating and preventing headaches30 Jul 2026US 2026/0217773 A1Neurocarrus Inc.
Most cited
By later US patents
- Lipophilic-polycationic delivery systems115US 6,005,004 AMolecular/Structural BioTechnologies, Inc. · 1999
- Recombinant toxin fragments113US 6,461,617 B1Microbiological Research Authority · 2002
- Peptide-based in vivo siRNA delivery system99US 8,501,930 B2Arrowhead Madison Inc. · 2013
- B/B-like fragment targeting for the purposes of photodynamic therapy and medical imaging98US 6,631,283 B2Virginia Tech Intellectual Properties, Inc. · 2003
- Methods and compositions for the treatment of pancreatitis96US 6,843,998 B1Allergan, Inc. · 2005